ClinicalTrials.gg
Not yet recruitingNCT07617298Updated Jun 1, 2026

EIT Evaluation of the Impact of Inhaled Nitric Oxide on Ventilation/Perfusion Mismatch in ARDS Patients Receiving Noninvasive Respiratory Support

An observational study in ARDS (Acute Respiratory Distress Syndrome), sponsored by Ming Zhong. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Ming Zhong · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
20th of 28
40 · median 103
Started
2026
with 7 others
Observational
28 of 59
10 open now
Primary completion
2027-12
later than 15 of 19 live
Registered
57th of 59
by date
Lead sponsor
2 of 59
Ming Zhong

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 20th largest by planned enrollment of the 28 observational ones that give a count, is one of 8 that started in 2026, is one of 28 observational ones, reaches primary completion later than 15 of the 19 other live ones, and was the 57th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

This study aimed to quantitatively evaluate the immediate effect of inhaled nitric oxide on the ventilation / perfusion ratio in ARDS patients receiving nasal high flow oxygen therapy or noninvasive ventilation using electrical impedance tomography.

Read the detailed description

The immediate effect of different doses of iNO (5-40 ppm) on the degree of v/q mismatch in the lungs of ARDS patients receiving hfnc or NIV was quantitatively evaluated by EIT. Objective to explore the effects of different doses of iNO on oxygenation, ventilation distribution and perfusion distribution in ARDS patients using hfnc or NIV, as well as the differences and influencing factors of individual response.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Browse trials for

Keywords

  • ARDS
  • inhaled nitric oxide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Non invasive ventilation (NIV) with PEEP or CPAP ≥ 5 cmH2O or nasal high flow oxygen therapy (hfnc) with flow rate ≥ 30 l/min met the diagnostic criteria of non intubated ARDS according to the new global definition of ARDS: pao2/fio2 ≤ 300MMHG or spo2/fio2 ≤ 315 (SpO2 ≤ 97%);

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, gender unlimited;
  2. Non invasive ventilation (NIV) with PEEP or CPAP ≥ 5 cmH2O or nasal high flow oxygen therapy (hfnc) with flow rate ≥ 30 l/min met the diagnostic criteria of non intubated ARDS according to the new global definition of ARDS: pao2/fio2 ≤ 300MMHG or spo2/fio2 ≤ 315 (SpO2 ≤ 97%);
  3. Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;
  4. Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;

Exclusion criteria

Exclusion Criteria:

  1. There are signs of worsening respiratory failure requiring immediate intubation: respiratory rate > 40 times / min with severe use of auxiliary respiratory muscles or contradictory breathing, or Paco ₂ > 50 mmHg and pH \< 7.25;
  2. Hemodynamic instability or the presence of shock; That is, the vasoactive drugs increased by more than 30% within 6 hours, or the norepinephrine dose exceeded 0.5 μ g /kg/min;
  3. There are to EIT monitoring, such as thoracic implantable defibrillator / pacemaker, large area of severe skin damage on the chest, serious allergy to electrode patches, etc;
  4. There are contraindications to the use of iNO: such as severe left ventricular dysfunction, active bleeding, etc;
  5. Patients with intracranial hypertension, severe arrhythmia or digestive tract obstruction;
  6. Pneumothorax and massive pleural effusion were not treated;
  7. Chronic kidney disease;
  8. Pregnant or lactating women;
  9. Participating in other studies;
  10. The investigator judged that there were any other circumstances not suitable for participation in this study. -
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Using transnasal high flow

    ARDS patients using high nasal flow

    Device: Inhale different doses of nitric oxide

  • Use a non-invasive mask

    ARDS patients using non-invasive face masks

    Device: Inhale different doses of nitric oxide

Interventions

  • DeviceInhale different doses of nitric oxide

    T0 (baseline): 20 to 30 minutes after initial stabilization; T1 (iNO 5ppm 1h): The patient non invasively inhales 5ppm NO for 1h. If the reaction standard (PaO2/FiO2 improvement ≥ 20%) is met, maintain the dose until the end of the study. Otherwise, continue to double the NO concentration and proceed with the following steps:; T2 (iNO 10ppm 1h): The patient non invasively inhales 10ppm of NO for 1h. If the reaction standard is met, maintain the dose until the end of the study, otherwise continue to double the NO concentration and proceed with the following steps; T3 (iNO 20ppm 1h): The patient non invasively inhales 20ppm NO for 1h. If the reaction standard is met, maintain the dose until the end of the study, otherwise continue to double the NO concentration and proceed with the following steps; T4 (iNO 40ppm 1h): The patient non invasively inhales 40ppm NO for 1h. All subjects completed the evaluation regardless of whether they met the response criteria.

  • DeviceInhale different doses of nitric oxide

    T0 (baseline): 20 to 30 minutes after initial stabilization; T1 (iNO 5ppm 1h): The patient non invasively inhales 5ppm NO for 1h. If the reaction standard (PaO2/FiO2 improvement ≥ 20%) is met, maintain the dose until the end of the study. Otherwise, continue to double the NO concentration and proceed with the following steps:; T2 (iNO 10ppm 1h): The patient non invasively inhales 10ppm of NO for 1h. If the reaction standard is met, maintain the dose until the end of the study, otherwise continue to double the NO concentration and proceed with the following steps; T3 (iNO 20ppm 1h): The patient non invasively inhales 20ppm NO for 1h. If the reaction standard is met, maintain the dose until the end of the study, otherwise continue to double the NO concentration and proceed with the following steps; T4 (iNO 40ppm 1h): The patient non invasively inhales 40ppm NO for 1h. All subjects completed the evaluation regardless of whether they met the response criteria.

06

What researchers measure

Primary outcomes

  1. Oxygenation index

    Blood gas analyzer was used for analysis after arterial extraction

    Time frame: baseline, before intervention; Time point 1: After inhaling 5ppm of NO for 1 hour; Time point 2: After inhaling 10ppm of NO for 1 hour; Time point 3: After inhaling 20ppm of NO for 1 hour; Time point 4: After inhaling 40ppm of NO for 1 hour

  2. Ventilation/perfusion ratio

    Electrical impedance tomography

    Time frame: baseline, before intervention; After inhaling 5ppm of NO for 1 hour; After inhaling 40ppm of NO for 1 hour

07

Study locations

1 site
  • Nitric Oxide Therapy Device
    Shanghai, 200000, China
    • Nanjing Nuoling Biotechnology Co., Ltd Nuoling Nanjing Nuoling · Contactcontact@novlead.com · 025-58222737-8001
    • Liu Kai Kai Liu, bachelor · Principal investigator
    • Dang Xinya Xinya Dang, bachelor · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — All IPDs collected during the trial period

Supporting information: Study protocol

Time frame: 2027/6/30-2028/12/30

Access criteria: publish a paper

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
Jun 1, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617298
Lead sponsor
Ming Zhong
Responsible party
Ming Zhong (deputy director, Shanghai Zhongshan Hospital) — Sponsor-investigator
First posted
Jun 1, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Dang Xinya Dang Xinya, bachelor
Contact
dang.xinya@zs-hospital.sh.cn
+86 158 2199 3005
Liu Kai Liu Kai, bachelor
Contact
Liu.kai1@zs-hospital.sh.cn
+86 135 1213 6346
Liu Kai Liu Kai, bachelor
principal investigator · Fudan University
Dang Xinya Xinya Dang, bachelor
study chair · Fudan University
Zhong Ming Ming Zhong, doctor
study director · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion